Background: We compared survival outcomes and risk of venous thromboembolism
INTRODUCTION
Epithelial ovarian cancer comprises various histologic subtypes, including ovarian clear cell carcinoma (OCCC), which represents the second most common histologic subtype. 1, 2 Accumulating evidence suggests that OCCC has distinct clinical and molecular characteristics compared with other histologic subtypes of epithelial ovarian cancer. 3, 4 Clinically, patients with advanced-stage OCCC have poorer survival outcomes than those with advanced-stage serous ovarian carcinoma (SOC), whereas patients with early-stage OCCC and SOC have similar survival outcomes. 5, 6 However, the reasons for this discrepancy and the mechanisms leading to poor survival outcomes in patients with advanced-stage OCCC have yet to be completely elucidated.
Venous thromboembolism (VTE) is a relatively common complication in ovarian
cancer and is associated with decreased survival outcomes. 7, 8 Epidemiologic studies have
shown that patients with OCCC have an increased risk of VTE compared with patients with other histologic subtypes of epithelial ovarian cancer, and VTE adversely affects survival outcomes in patients with OCCC. [9] [10] [11] One possible biomarker linking OCCC with the increased risk of VTE is the proinflammatory cytokine interleukin 6 (IL-6). OCCC is known to be associated with higher IL-6 expression than in other subtypes of epithelial ovarian cancer, 12 and IL-6 is a pivotal marker of paraneoplastic thrombocytosis, which is a prognostic factor for decreased survival of ovarian cancer. 13, 14 IL-6 could directly increase the risk of VTE by inducing procoagulant factors or indirectly increase the risk by inducing thrombocytosis. 15, 16 However, it is unclear whether VTE events and IL-6 levels differ by stage of disease. The aim of our study was to compare the survival outcomes and risk of VTE among patients with early-and advanced-stage OCCC and SOC, as well as to examine the relationship of these outcomes to IL-6 levels.
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PATIENTS AND METHODS
Clinical information
A large-scale multicenter international case-control study was conducted in 10 academic institutions, including 5 from the United States, 4 from Japan, and 1 from England.
Institutional Review Board approval was obtained at each participating institution.
Consecutive patients diagnosed with OCCC and SOC between January 1, 2000 and December 31, 2012 were identified from institutional databases. The STROBE guidelines for case-control studies were followed. 17 All patients had primary OCCC or SOC that was histologically confirmed from surgical specimens obtained in cytoreductive surgery. Those with a mixed histologic type were excluded from our analysis. A fraction of this study population was used in our previous study. 13 Medical records were retrospectively reviewed to obtain the following data: age, tumor markers, cytoreductive status, VTE characteristics, tumor characteristics, and survival outcomes.
Tumor markers included CA-125 levels and the presence of thrombocytosis (based on platelet counts) at the time of diagnosis. The cutoff for thrombocytosis (platelet count ≥400 ×10 9 /L) was determined on the basis of prior work. 18 For survival outcomes, we determined progression-free survival (PFS) and overall survival (OS). PFS was defined as the time interval between the date of ovarian cancer diagnosis and the date of the first recurrence or progression of disease or last follow-up if there was no recurrence or progression. OS was defined as the time interval between the date of ovarian cancer diagnosis and the date of death or last follow-up if the patient was still alive. OS after first recurrence or progression was also examined in the subset of patients who experienced recurrence or progression.
IL-6 measurement
Pretreatment plasma samples were available for consecutive patients in 2 institutions.
Blood samples were obtained prior to surgery and centrifuged at 3,000 rotations per minute for 10 minutes. Plasma was collected and stored in 1-mL aliquots in a -80°C freezer until it was processed. Plasma levels of IL-6 were examined using a Human IL-6 Quantikine enzyme-linked immunosorbent assay (ELISA) Kit (R&D Systems, Minneapolis, MN), according to the manufacturer's instructions. The ELISA plates were read using Multiskan JX (ThermoFisher Scientific, Waltham, MA). All tests were done in triplicate. Written informed consent was obtained from each subject prior to the blood sampling.
Statistical analysis
The primary outcome of interest was the impact of stage-specific histologic subtype (advanced-OCCC, advanced-SOC, early-OCCC, or early-SOC) on cumulative risk of VTE and survival outcomes. The secondary outcomes of interest were the correlation between 7 IL-6 levels and VTE incidence and between IL-6 levels and survival outcomes, by 
RESULTS
Patient characteristics
We evaluated the records of 1,308 patients with ovarian cancer for the current study.
Although most of the 938 patients with SOC had advanced disease (n=836, 89.1%), most of the 370 patients with OCCC had early-stage disease (n=264, 71.4%; Table S1 ).
Stage-specific characteristics are shown in Table 1 . The mean age of the entire cohort was 58.5 years. Both the advanced-OCCC and advanced-SOC groups had a high proportion of patients with elevated CA-125 levels at the initial cancer diagnosis (advanced-OCCC 96.2%, and advanced-SOC 87%). The advanced-SOC group had the highest proportion of patients with thrombocytosis at initial diagnosis (41.6%), followed by the advanced-OCCC group (32.1%). The advanced-SOC group had the highest proportion of patients with residual tumor size >1 cm at cytoreductive surgery (37.6%), followed by advanced-OCCC (26.4%). The median follow-up time of the entire cohort was 31.3 months, and there were 787 cases of recurrent or progressive disease (60.2%) and 487 deaths (37.2%) reported in the records.
Characteristics of VTE
There were 215 VTEs reported in the entire cohort (16.4%). DVT alone (n=102, 47.4%)
was the most common type of VTE, followed by PE alone (n=56, 26.0%) and DVT+PE (n=51, 23.7%). The advanced-OCCC group had the highest incidence of any VTE (36.8%) among the 4 groups, as well as the highest incidence of DVT+PE (11.3%, P<0.0001, Table   1 ).
The cumulative prevalence of VTE was examined by stage-specific histologic subtype ( Table 2) . In univariate analysis, advanced-OCCC was associated with the highest 9 cumulative risk of VTE among the 4 groups (2-year cumulative VTE rates, To identify independent risk factors for VTE, we performed multivariate analysis ( 
Recurrent or progressive tumors
In our cohort, 787 patients experienced recurrence or progression. Among these patients, prognostic factors for OS after the first recurrence or progression of the tumor were examined ( Table 4) . Patterns of CA-125 and thrombocytosis at recurrence or progression were distinctively different from those at the initial ovarian cancer diagnosis. Specifically, CA-125 levels were similar across the 4 stage-specific histologic subtype groups (P=0.38).
Although thrombocytosis was more common in those with advanced-SOC (41.6%) than in those with advanced-OCCC (32.1%) at the time of the initial cancer diagnosis, at the time of the first recurrence or progression, thrombocytosis was more common in those with 11 advanced-OCCC (27.0%) than in those with advanced-SOC (13.6%, P=0.028).
Splenectomy at the time of cytoreductive surgery (n=15, 1.1%) was not associated with thrombocytosis at the time of the first recurrence or progression of disease (9.1% vs.
15.1%, P=1.0).
The median OS duration after the first recurrence or progression was 13.0 months.
In the multivariate analysis controlling for age, CA-125, thrombocytosis, VTE, and stagespecific histologic subtype, thrombocytosis at the first recurrence or progression remained an independent prognostic factor for decreased 2-year OS rates after the first recurrence or prognostic factors for decreased 2-year OS rates after the first recurrence or progression compared to advanced-SOC (Table 4 and Fig. 1C ).
IL-6 levels
Plasma samples were available for 200 patients in the cohort (OCCC n=38, and SOC n=162). The median plasma IL-6 level among these 200 patients was 7.6 pg/mL, and 85 of the patients (42.5%) had IL-6 levels ≥10 pg/mL. Table 5 ).
Across the 4 stage-specific histologic subtype groups, the advanced-OCCC group had the highest proportion of IL-6 levels ≥10 pg/mL (advanced-OCCC 83.3%, advanced-SOC 47.7%, early-OCCC 15.6%, and early-SOC 27.3%, P=0.001, Fig. 1D) . Similarly, the advanced-OCCC group had the highest median IL-6 levels among the 4 groups (advanced-OCCC 17.8 pg/mL, advanced-SOC 9.0 pg/mL, early-OCCC 4.2 pg/mL, and early-SOC 5.0 pg/mL, P=0.006). Similar to the results from the entire cohort, advanced-OCCC was associated with the highest risk of VTE across the 4 groups (2-year cumulative VTE risk:
advanced-OCCC 40%, advanced-SOC 13.4%, early-OCCC 17.5%, and early-SOC 0%,
P=0.039).
Among the 200 patients in whom IL-6 levels were examined, IL-6 levels ≥10 pg/mL were associated with decreased 2-year PFS rates (27.4% vs. 47.6%; HR 1.58, 95%CI Fig. 1F ).
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DISCUSSION
In the current study, advanced-OCCC, but not early-OCCC, was associated with a substantially increased risk of VTE compared with advanced-SOC. Patients with advanced-OCCC also had the highest frequency of elevated IL-6 levels, and those with advanced-OCCC had poorer survival outcomes than those with advanced-SOC. These findings suggest that the IL-6 pathway plays a pivotal role in the progression of OCCC. A proposed schema of the role of IL-6 in OCCC, based on our results, is shown in Figure S1 .
A recent study showed that paraneoplastic thrombocytosis contributed to poor outcomes in ovarian cancer. The authors showed that IL-6 stimulates hepatocytes to induce thrombopoietin, which further induces megakaryocytes in bone marrow to produce platelets. 13 These IL-6-induced platelets promote tumor progression by providing plateletrelated cancer cell protection from the host immune system, providing growth factors, and promoting tumor angiogenesis. In our study, survival analyses showed that both advanced-OCCC and thrombocytosis were the common prognostic factors for decreased survival outcomes (Table 3-4) . In addition, elevated IL-6 levels were associated with thrombocytosis and advanced disease. These findings provide evidence for the existence of IL-6-mediated paraneoplastic thrombocytosis in advanced-OCCC.
Although IL-6-mediated paraneoplastic thrombocytosis is a proposed mechanism for tumor progression in advanced-OCCC, our study showed that thrombocytosis was less common in patients with advanced-OCCC than in those with advanced-SOC (32.1% vs.
41.6%, Table 1 ). This implies that the IL-6-mediated paraneoplastic thrombocytosis is more prominent in SOC, and there may be an alternative IL-6-related pathway that contributes to tumor progression in OCCC, such as a direct autocrine pathway. Recently, the tumor microenvironment was reported to be a source of IL-6 in certain types of 14 malignancy. 20, 21 Some researchers have even speculated that the tumor microenvironment may supply IL-6 in SOC. 22 Therefore, hypothetically, there are 2 possible pathways for IL-6 interaction in ovarian cancer: (i) direct pathway via autocrine IL-6 signaling and (ii) IL-6-mediated indirect pathway via paraneoplastic thrombocytosis. 13, 22 In the IL-6 autocrine pathway in OCCC, downstream signaling of the IL-6 receptor is activated via the HIF1A-STAT3 cascade and ultimately induces VEGF, a key mediator for tumor angiogenesis. 12, 23, 24 Indeed, VEGF expression in OCCC is significantly higher than in other histologic types of epithelial ovarian cancer. 25 Collectively, our findings suggest that both direct and indirect IL-6 pathways may lead to tumor progression in OCCC, and the direct pathway may be more active in OCCC.
VTE is a common issue in OCCC. 10 Quality of life in cancer patients can be compromised as a result of the VTE itself and from drug injections, treatment costs, and decreased survival outcomes. In our study, those with VTE had significantly higher levels of IL-6 than those who did not have VTE, and this association has not been well studied in cancer patients. 26 In addition, VTE was associated with thrombocytosis (Table 2) , which has recently been recognized in the oncology field. 27 Our findings also showed that elevated IL-6 is associated with thrombocytosis, and those with advanced-OCCC had the highest frequency of multiple-site VTE (DVE+PE; 11.3%) compared with the other groups.
Taken together, our findings indicate that VTE in OCCC is a clinical manifestation and surrogate marker of the aggressiveness of IL-6-driven tumor progression, and the decreased survival outcomes in those who develop VTE among OCCC patients is more likely from the aggressive tumor behavior than from cardiovascular collapse.
Although overexpression of IL-6 in OCCC has been reported by various investigators, the exact mechanism driving IL-6 overexpression in OCCC has yet to be 15 determined. 28 Although a fraction of IL-6 may come from the tumor microenvironment, a substantial fraction of IL-6 is speculated to come from tumor cells in OCCC given its high IL-6 expression. To date, ARID1A mutation (loss of function) and PIK3CA mutation (gain of function) have been identified as common occurrences in OCCC (40-60%). 2, 29 Available evidence suggests a possible link between the PIK3CA mutation and IL-6 overexpression.
Specifically, the PIK3CA mutation upregulates NF-κB, which leads to IL-6-dependent STAT3 activation. 30 Moreover, a recent pre-clinical study has shown that additional loss of ARID1A function in the setting of PIK3CA overexpression is a key step in pathogenesis of OCCC. 31 Interestingly, IL-6 transcription in this OCCC model of ARID1A and PIK3CA mutation is found to be elevated. Therefore, it is paramount to see if this correlation seen in pre-clinical study also exists in human samples of OCCC by sequencing ARID1A and PIK3CA correlating with plasma IL-6 level.
The unique characteristics of recurrent or progressive OCCC deserve further discussion. Generally, recurrent OCCC is resistant to therapy, with a response rate of <10%. 32 This was also true in our study, and those with advanced-OCCC had poorer 2-year OS rates after recurrence or progression than those with advanced-SOC ( Table 5 ).
The advanced-OCCC group had a higher proportion of patients with thrombocytosis at the first recurrence or progression than the other groups, and this may represent a role for paraneoplastic thrombocytosis in the setting of advanced-OCCC. Interestingly, 2-year OS rates after recurrence or progression were also shorter in those with early-OCCC than in those with advanced-SOC. This implies that recurrent or progressive OCCC is quite chemoresistant regardless of original disease status. Our study did not have information for chemotherapy treatment after the first recurrence or progression and therefore we were unable to address this question. 16 A potential limitation of our study is that this is a retrospective study that may have some confounding factors. For example, we did not use the standard case record form to capture VTE events; however, all the participating institutions are tertiary care cancer centers and patient follow-up is quite consistent. In addition, central pathology review to confirm OCCC was not performed for the study. A potential weakness of our study is that central histopathologic slide review was not available for grading serous tumors. 32 Nevertheless, in post-hoc analysis, high-grade SOC cases (n=768) were compared to CCC cases (Table S3-6) . 33 The results were consistent in that advanced-OCCC was significantly associated with increased risk of VTE (HR 3. analysis. Lastly, a relatively small sample size for IL-6 assessment may limit generalizability.
In summary, our results indicate that advanced-OCCC is thrombogenic and may be a surrogate marker of tumor-biologically more aggressive disease. Treatment involving both anti-thrombotic agents and blocking of IL-6 signaling may be an attractive approach in advanced-OCCC. A phase II study examining the efficacy of the combination of a monoclonal antibody against IL-6 with siltuximab for platinum-resistant ovarian cancer showed that the combination had some therapeutic activity; however, this study was not solely for patients with OCCC. 35 Statin therapy is also suggested to reduce IL-6 activity and VTE risk by inhibiting inflammatory cytokines, resulting in reduced cancer-related mortality. 36, 37 Currently (as of April 8, 2015) , no ongoing clinical trial of a treatment targeting IL-6 for 17 OCCC has been registered at clinicaltrials.gov. Further preclinical and clinical studies are warranted. *Platelet count ≥400 × 10 9 /L. **IL-6 levels were grouped into lower third (1-33%ile, <5 pg/mL), mid third (34-66%ile, 5-19.9 pg/mL), and upper third (≥67%ile, ≥20 pg/mL). Proportion of patients with IL-6 levels ≥10 pg/mL (prior to treatment), by stage-specific histologic subtype. E) Progression-free survival by IL-6 level in patients with ovarian clear cell carcinoma (OCCC). F) Progression-free survival by IL-6 level in patients with serous ovarian carcinoma (SOC).
Abbreviations: HR, hazard ratio.
